Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of two poster presentations that focus on the use of Copanlisib for relapsed or refractory follicular lymphoma and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Poster #7535: Copanlisib in patients with relapsed or refractory follicular lymphoma Poster #7536: Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Author: Editor
Mark Rutstein, Vice President of Oncology Development of Bayer discusses Bayers current and approved products and new and diverse advances for its robust oncology pipeline. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of the ARASENS study, which is a phase 3 trial on the use of darolutamide for men with metastatic hormone-sensitive prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #TPS5092: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Howard S. Hochster, MD of Yale School of Medicine gives an overview of his presentation, The Impact of Molecular Subsets on Adjuvant and Advanced Disease Treatment, which was discussed at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Howard S. Hochster, MD of Yale School of Medicine discusses the importance of recommending molecular testing early on to patients with colon cancer. He further explains the significance of HER2 testing in colon cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Howard S. Hochster, MD of Yale School of Medicine discusses the impact of molecular testing and screening on potential clinical trials at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Christopher Crane, MD of Memorial Sloan-Kettering gives an overview of his presentation, What is the Optimal Neoadjuvant Strategy in Pancreatic Cancer, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Christopher Crane, MD of Memorial Sloan-Kettering gives an overview of his presentation, Does Radiation Therapy Play a Role in Gastric Cancer Adjuvant Therapy, which was debated with Dr. David Ilson, MD, PhD of Memorial Sloan-Kettering. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Mark A. Schattner, MD of Memorial Sloan-Kettering gives an overview of his presentation, Novel Endoscopic Management of Pancreaticobiliary Cancers, which was presented at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Mark A. Schattner, MD of Memorial Sloan-Kettering explains whether or not there is screen for pancreatic cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
David Ilson, MD, PhD of Memorial Sloan-Kettering discusses questions from the audience that focused on the appropriate chemotherapy for gastric cancer treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
David Ilson, MD, PhD of Memorial Sloan-Kettering explains the impact of radiation therapy on clinical practice. He argues that adding radiation therapy as an obligatory part of adjuvant therapy does not improve overall survival. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
David Ilson, MD, PhD of Memorial Sloan-Kettering gives an overview of his presentation, Debate: Does Radiation Therapy Play a Role in Gastric Cancer Adjuvant Therapy, which was debated with Dr. Christopher Crane, MD of Memorial Sloan-Kettering. He argues that adjuvant radiation therapy adds no benefit to treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses his presentation, Overview of Novel Treatments for HCC in the Era of Hep C Therapies, which was discussed at the 2016 Great Debates and Updates in GI Malignancies in New York, NY
Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses the impact of regorafenib for hepatocellular carcinoma (HCC) treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Jonathan R. Strosberg, MD of Moffitt Cancer Center gives an overview of his presentation, Management of Neuroendocrine Tumors, which was discusses at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Jonathan R. Strosberg, MD of Moffitt Cancer Center discusses the impact of circulating tumor DNA on oncology treatment and management. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Jonathan R. Strosberg, MD of Moffitt Cancer Center gives an overview of his presentation, Is There a Role for Surgical Management of Metastatic Neuroendocrine Cancer, which was debated with Dr. Michael Choti, MD, MBA of UT Southwestern Medical Center. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Yelena Yuriy Janjigian, MD, Memorial Sloan-Kettering gives an overview of her presentation, Molecular Subtyping/Profiling and Update in HER2 Targeted Therapy, which was discussed at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Yelena Yuriy Janjigian, MD of Memorial Sloan-Kettering explains whether or not PDL-1 is a sufficient biomarker in gastric disease. She argues that clinicians should consider a one-stop next generation sequencing. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, New York.
Yelena Yuriy Janjigian, MD of Memorial Sloan-Kettering discusses her presentation, Is Surgery Required After Chemoradiotherapy for Squamous Cancer of the Esophagus, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY. She argues that surgery is a must after chemo-radiation.
http://cancertherapeutics.alliedacademies.com/
Cathy Eng, MD, FACP of MD Anderson Cancer Center discusses her second presentation, which focused on management of anal carcinoma. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Cathy Eng, MD, FACP of MD Anderson Cancer Center gives an overview of her first presentation, Is Circulating Tumor DNA Ready to Guide Adjuvant Therapy in Colon Cancer, which was debated with Dr. Axel Grothey of Mayo Clinic, at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Michael Choti, MD, MBA of UT Southwestern Medical Center gives an overview of his presentation, Is There a Role for Surgical Management of Metastatic Neuroendocrine Cancer, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Michael Choti, MD, MBA of UT Southwestern Medical Center discusses questions from the audience on how to manage early stage neuroendocrine tumors or tumors that are incidentally found. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Zsofia K. Stadler, MD of Memorial Sloan-Kettering explains the role of aspirin therapy in patients with colon cancer and other GI malignancies. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Zsofia K. Stadler, MD of Memorial Sloan-Kettering gives an overview of her second presentation, which focused on the role of genetics in gastrointestinal cancers. She further discusses who should be tested for hereditary syndromes and why. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic gives an overview of his second presentation, which focused on optimal adjuvant chemotherapy for resected pancreatic cancer. He further explains the use of gemcitabine and capecitabine for treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains whether or not there is a standard second line treatment for patients with hepatocellular carcinoma (HCC) and who failed first line therapy. He argues that Regorafenib should be used for second line therapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic gives an overview of his first presentation, which focused on the availability of new novel agents and therapies for managing patients with metastatic colorectal cancer. He discusses the uses of HER2, BRAF, and Immunotherapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains how to integrate HER2, BRAF, and immunotherapy into clinical practice. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Eric Van Cutsem, MD, PhD of University of Leuven gives an overview of his presentation which focused on how to treat left-sided tumors versus right-sided tumors in colorectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Eric Van Cutsem, MD, PhD of University of Leuven gives an overview of his second presentation, which focused on the role of novel agents in colorectal cancer patients. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Eric Van Cutsem, MD, PhD of University of Leuven discusses the impact of left-sided tumors versus right-sided tumors on research in colorectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center discusses the use of technology and its potential breakthroughs for managing patients with colon cancers at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center gives an overview of his presentation, which focused on treatment of left versus right sided colon cancers. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center gives an overview of the novel therapies that are being used for colon cancer treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Christopher Leigh Hallemeier, MD of Mayo Clinic gives an overview of Dr. Julio Garcia-Aguilar’s latest research trial, A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management, at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Christopher Leigh Hallemeier, MD of Mayo Clinic gives an overview of his presentation, Is Observation Without Surgery Reasonable for Rectal Cancers Achieving a Clinical CR, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Christopher Leigh Hallemeier, MD of Mayo Clinic explains whether or not clinicians can use non-operative management for patients with stage I rectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering gives an overview of new data regarding watch-and-wait approaches in patients with rectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering gives an overview of his presentation, Is Observation Without Surgery Reasonable for Rectal Cancers Achieving a Clinical CR, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering discusses patient concerns of risks with delaying surgery months or years after receiving neoadjuvant therapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
http://cancertherapeutics.alliedacademies.com/ Cancer Therapeutics 2017 will be a great platform for research scientists and young researchers to share their current findings in the field of applied sciences.
Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center gives an overview of her presentation, which discusses the survivorship care basics for survivors of colorectal cancer. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.
Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center gives an overview of her poster presentation, which was a 12-week home-based walking intervention for patients with advanced pancreatic cancer. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.
Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center explains the importance of clinicians speaking about diet, exercise, and healthy living with colorectal cancer survivors. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.
Becky Lowry, MD of University of Kansas Medical Center gives an overview of her presentation, Survivorship Transitions to Adulthood and Using Telemedicine in Rural Areas, which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.
Becky Lowry, MD of University of Kansas Medical Center discusses the importance of communication between clinicians and survivors during survivorship care. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.